Our data demonstrate that pancreatic cancer may share some of the same biologic characteristics as breast cancer with regards to HER-2/neu and AKT signalling, generating some enthusiasm for targeted HER-2/neu or AKT therapy in this lethal malignancy. This evidence concerns the gene ERBB2 and breast carcinoma.